SCHEMBL4064446

SCHEMBL4064446

C=CCCc1cccc(CNC(=O)O)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.54
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
KCNH2 Q12809 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 3/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 2/20 0.35
ALOX15 P16050 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP3A4 P08684 1/20 0.35
TP53 P04637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4072737 0.84 NPSR1 (0.53) NPSR1CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL4064830 0.81 NPSR1 (0.61) NPSR1CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL3747154 0.77 NPSR1 (0.59) NPSR1CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL4071518 0.77 NPSR1 (0.56) NPSR1CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL4073677 0.76 NPSR1 (0.58) NPSR1CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL20524911 0.76 NPSR1 (0.58) NPSR1CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL20525055 0.76 NPSR1 (0.58) NPSR1CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL13734815 0.74 NPSR1 (0.59) NPSR1CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL21874081 0.72 NPSR1 (0.53) NPSR1CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL15578010 0.72 NPSR1 (0.53) NPSR1CYP1A2CYP2C9CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049490-A1 N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL]-L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS Astra Zeneca AB (SE) 2009-04-22 EP disclosed
US-20080045521-A1 PHENYLALANINE DERIVATIVES ASTRAZENECA AB (SE) 2008-02-21 US disclosed
WO-2007141473-A1 N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS ASTRAZENECA AB (SE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045521-A1 PHENYLALANINE DERIVATIVES ITGB5, ITGB1, ITGA2B NPSR1 943/4885CYP1A2 3894/4885CYP2C9 4348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.